Astel­las cuts a bis­pe­cif­ic in can­cer and a mi­to­chon­dria-fo­cused as­set from Mi­to­bridge deal

Astel­las said it has re­moved a Phase 1 can­cer as­set as well as a small mol­e­cule that came from its Mi­to­bridge ac­qui­si­tion.

The Japan­ese phar­ma will no longer test the TSPAN8 and CD3 bis­pe­cif­ic known as ASP2074, nor its PPARδ mod­u­la­tor ASP0367, ac­cord­ing to Astel­las’ lat­est earn­ings re­port for the fis­cal year end­ing March 31.

ASP0367 came by way of Astel­las’ rel­a­tive­ly small ac­qui­si­tion of mi­to­chon­dria-fo­cused Mi­to­bridge in 2017. The phar­ma com­pa­ny was in­ves­ti­gat­ing the small mol­e­cule in pa­tients with pri­ma­ry mi­to­chon­dr­i­al my­opathies in Phase 2 and pa­tients with Duchenne mus­cu­lar dy­s­tro­phy in Phase 1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER